GNW: Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a
Oct 16, 2020 - AWP OTS (Original Text Service)
potential first-in-class siRNA for the treatment of high cholesterol
* If approved, inclisiran will be the first and only small interfering RNA(siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1
* Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2,and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread use of statins3-5
* Inclisiran provides eff...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
